Source: Eur Respir J 2012; 39: 1475-1481



Rating:

Share or cite this content

Citations should be made in the following way:
Schuurhof Annemieke, Bont Louis, Hodemaekers Hennie M., de Klerk Arja, de Groot Hanneke, Hofland Regina W., van de Pol Alma C., Kimpen Jan L.L., Janssen Riny. Proteins involved in extracellular matrix dynamics are associated with respiratory syncytial virus disease severity. Eur Respir J 2012; 39: 1475-1481

Member's Comments

No comment yet.

Related content which might interest you: Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005 Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF Source: Eur Respir J 2002; 20: 1220-1227 Year: 2002 Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006 Impact of acute exposure to tobacco smoke on gelatinases in the bronchoalveolar space Source: Eur Respir J 2008; 32: 644-650 Year: 2008 Matrix metalloproteinases (MMPs) and angiogenesis in lung tissue remodeling in different variants of idiopathic interstitial pneumonia (IIP) Source: Eur Respir J 2007; 30: Suppl. 51, 137s Year: 2007 Biological role of matrix metalloproteinases: a critical balance Source: Eur Respir J 2011; 37: 191-208 Year: 2011 A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Source: Eur Respir J 2011; 38: 1200-1214 Year: 2011 Balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in the development of bronchiolitis obliterans syndrome after lung transplantation Source: Eur Respir J 2003; 22: Suppl. 45, 327s Year: 2003 Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012 Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004 Regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases expression in the bronchial secretions of asthmatics and COPD Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002 High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation Source: Eur Respir J 2009; 33: 134-141 Year: 2009 Sputum matrix metalloproteinase-9 and tissue inhibitor of matrix metalloprotienase-1 levels in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006 Statins inhibit matrix metalloproteinase release from human lung fibroblasts Source: Eur Respir J 2010; 35: 637-646 Year: 2010 Extracellular matrix components and regulators in the airway smooth muscle in asthma Source: Eur Respir J 2008; 32: 61-69 Year: 2008 Matrix metalloproteinases in acute lung injury: mediators of injury and drivers of repair Source: Eur Respir J 2011; 38: 959-970 Year: 2011 Blood levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix matalloproteinases (TIMPs) as biomarkers of COPD. Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018 Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation Source: Eur Respir J 2005; 25: 494-501 Year: 2005 Matrix metalloproteinase (MMP) 12 is associated with clinical parameters of disease severity and exacerbations in asthma Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010